Article Text

Download PDFPDF
Letter
Immunogenicity to infliximab is associated with HLA-DRB1

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors TB: data acquisition and interpretation, statistical analysis and drafting of the manuscript; NvdC: data acquisition and interpretation, critical revision of the manuscript; TvS: data acquisition and critical revision of the manuscript; AG, MF, GVA and IC: critical revision of the manuscript; SV: study concept—design and supervision, critical revision of the manuscript; FP and SS: technical support.

  • Funding FWO Vlaanderen (G.0617.12).

  • Competing interests NvdC received a lecture fee from Abbvie and consultancy fees from MSD, Janssen Biotech, UCB and Pfizer. FP and SS are employees of Prometheus Laboratories. AG received financial support for research from FWO and lecture fees from MSD, Abbvie, Janssen Biologicals, Pfizer. MF received financial support for research from Janssen Biologics, lecture fees from MSD, Ferring Pharmaceuticals, Chiesi, MSD, Tillotts, Janssen Biologics, Abbott and Abbvie and consultancy fees from Abbott, Abbvie, MSD and Janssen Biologics. GVA received financial support for research from Abbott and Ferring Pharmaceuticals, lecture fees from Janssen, MSD and Abbott and consultancy fees from PDL BioPharma, UCB Pharma, Sanofi-Aventis, Abbott, Abbvie, Ferring, Novartis, Biogen Idec, Janssen Biologics, NovoNordisk, Zealand Pharma A/S, Millenium/Takeda, Shire, Novartis and Bristol Mayer Squibb. SV received financial support for research from MSD, Abbvie and UCB Pharma, lecture fees from Abbott, Abbvie, MSD, Ferring Pharmaceuticals and UCB Pharma and consultancy fees from Pfizer, Ferring Pharmaceuticals, Shire Pharmaceuticals Group, MSD and AstraZeneca Pharmaceuticals. TB, TVS and IC disclose no conflicts of interest.

  • Ethics approval Ethische commissie UZ Leuven.

  • Provenance and peer review Not commissioned; internally peer reviewed.